Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that
Out-of-the-box, Genedata Biologics supports diverse biologics R&D processes. The platform enables fully automated, high-throughput biopharmaceutical discovery and development workflows and can directly interact with laboratory instruments and robotics equipment. By increasing experimental throughput, minimizing data handling errors, and ensuring consistently high data quality standards, Genedata Biologics significantly improves efficiency in the discovery and development of novel protein-based therapeutics.
“We are delighted that
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in
Follow us on LinkedIn.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Read the full story at http://www.prweb.com/releases/Genedata_Biologics/Sanofi/prweb11279369.htm
Most Popular Stories
- Accenture Gets 8 Percent Bump in Q1
- Texting With Vodka: Booze and Social Media Can Mix After All
- Lockheed Martin Ends Gifts to Boy Scouts Over Gay Ban
- Stripped-Down Defense Bill Creates Winners, Losers
- Debt Ceiling Looms Again as Deadline Approaches
- Menendez Pushes for Iran Sanctions
- Deportation Threat Looms Larger Than Citizenship Among Hispanics
- How to Protect Yourself After Target Data Breach
- Mazda Leads the Pack for Fuel Efficiency
- Senate Nears Approval of Defense Bill